144 related articles for article (PubMed ID: 10673996)
21. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma.
Gill J; Bourboulia D; Wilkinson J; Hayes P; Cope A; Marcelin AG; Calvez V; Gotch F; Boshoff C; Gazzard B
J Acquir Immune Defic Syndr; 2002 Dec; 31(4):384-90. PubMed ID: 12447008
[TBL] [Abstract][Full Text] [Related]
22. AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparations.
Hermans P; Clumeck N; Picard O; van Vooren JP; Duriez P; Zucman D; Bryant JL; Gill P; Lunardi-Iskandar Y; Gallo RC
J Hum Virol; 1998; 1(2):82-9. PubMed ID: 10195236
[TBL] [Abstract][Full Text] [Related]
23. Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels.
Min J; Katzenstein DA
AIDS Res Hum Retroviruses; 1999 Jan; 15(1):51-5. PubMed ID: 10024052
[TBL] [Abstract][Full Text] [Related]
24. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia.
Bourboulia D; Aldam D; Lagos D; Allen E; Williams I; Cornforth D; Copas A; Boshoff C
AIDS; 2004 Feb; 18(3):485-93. PubMed ID: 15090801
[TBL] [Abstract][Full Text] [Related]
25. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.
Martinez V; Caumes E; Gambotti L; Ittah H; Morini JP; Deleuze J; Gorin I; Katlama C; Bricaire F; Dupin N
Br J Cancer; 2006 Apr; 94(7):1000-6. PubMed ID: 16570046
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe.
Borok M; Fiorillo S; Gudza I; Putnam B; Ndemera B; White IE; Gwanzura L; Schooley RT; Campbell TB
Clin Infect Dis; 2010 Aug; 51(3):342-9. PubMed ID: 20572760
[TBL] [Abstract][Full Text] [Related]
27. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage.
Campbell TB; Borok M; Gwanzura L; MaWhinney S; White IE; Ndemera B; Gudza I; Fitzpatrick L; Schooley RT
AIDS; 2000 Sep; 14(14):2109-16. PubMed ID: 11061651
[TBL] [Abstract][Full Text] [Related]
28. Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients.
Leao JC; Kumar N; McLean KA; Porter SR; Scully CM; Swan AV; Teo CG
J Med Virol; 2000 Dec; 62(4):416-20. PubMed ID: 11074468
[TBL] [Abstract][Full Text] [Related]
29. The effects of human herpesvirus 8 infection and interferon-gamma response in cutaneous lesions of Kaposi sarcoma differ among human immunodeficiency virus-infected and uninfected individuals.
Guedes F; de Andrade HF; Fernandes ER; Tuon FF; Brasil RA; Pagliari C; Duarte MI
Br J Dermatol; 2008 Sep; 159(4):839-46. PubMed ID: 18644020
[TBL] [Abstract][Full Text] [Related]
30. Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial.
Krown SE; Lee JY; Lin L; Fischl MA; Ambinder R; Von Roenn JH
J Acquir Immune Defic Syndr; 2006 Feb; 41(2):149-53. PubMed ID: 16394845
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy.
Boivin G; Gaudreau A; Routy JP
AIDS; 2000 Sep; 14(13):1907-10. PubMed ID: 10997393
[TBL] [Abstract][Full Text] [Related]
32. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma.
Engels EA; Biggar RJ; Marshall VA; Walters MA; Gamache CJ; Whitby D; Goedert JJ
AIDS; 2003 Aug; 17(12):1847-51. PubMed ID: 12891072
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus.
Cannon MJ; Dollard SC; Black JB; Edlin BR; Hannah C; Hogan SE; Patel MM; Jaffe HW; Offermann MK; Spira TJ; Pellett PE; Gunthel CJ
AIDS; 2003 Jan; 17(2):215-22. PubMed ID: 12545082
[TBL] [Abstract][Full Text] [Related]
34. Monitoring of endogenous interferon-alpha and human herpesvirus 8 in HIV-infected patients with Kaposi's sarcoma.
Plettenberg A; Albrecht D; Lorenzen T; Meyer T; Arndt R; Stoehr A
Eur J Med Res; 2002 Jan; 7(1):19-24. PubMed ID: 11827836
[TBL] [Abstract][Full Text] [Related]
35. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy.
Leitch H; Trudeau M; Routy JP
HIV Clin Trials; 2003; 4(2):107-14. PubMed ID: 12671778
[TBL] [Abstract][Full Text] [Related]
36. Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin.
Torre-Cisneros J; Pozo F; Serrano R; Vidal E; Rivero A; Tenorio A
AIDS; 2000 Sep; 14(14):2215-7. PubMed ID: 11061671
[No Abstract] [Full Text] [Related]
37. Risk factors for Kaposi's sarcoma in human immunodeficiency virus patients after initiation of antiretroviral therapy: A nested case-control study in Kenya.
Lupia R; Wabuyia PB; Otiato P; Fang CT; Tsai FJ
J Microbiol Immunol Infect; 2017 Dec; 50(6):781-788. PubMed ID: 26712092
[TBL] [Abstract][Full Text] [Related]
38. Isolated penile Kaposi's sarcoma in a HIV-positive patient stable on treatment for three years.
Lebari D; Gohil J; Patnaik L; Wasef W
Int J STD AIDS; 2014 Jul; 25(8):607-10. PubMed ID: 24492851
[TBL] [Abstract][Full Text] [Related]
39. Complete histological regression of Kaposi's sarcoma following treatment with protease inhibitors despite persistence of HHV-8 in lesions.
Benfield TL; Kirk O; Elbrønd B; Pedersen C
Scand J Infect Dis; 1998; 30(6):613-5. PubMed ID: 10225394
[TBL] [Abstract][Full Text] [Related]
40. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor.
Murdaca G; Campelli A; Setti M; Indiveri F; Puppo F
AIDS; 2002 Jan; 16(2):304-5. PubMed ID: 11807324
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
